Tellgen Corp (300642) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Tellgen Corp ¥2.32, price ¥21.21, upside -89.1%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range ¥10.28 – ¥45.32 · fair‑value band ¥1.72 – ¥3.08 · the ¥21.21 price screens above the ¥2.32 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Tellgen in your weekly email
Every Wednesday you see whether Tellgen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation.
Show more
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.
Stock analysis
Tellgen Corp (300642) currently trades at ¥21.21, while our model-based Fair Value estimate is ¥2.32, 89.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥5.89 per share, and 0 of the 25 models we run sit above the ¥21.21 price.
Bear case: the Growth Earnings group reads lowest at ¥0.4300, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.72 (bear) to ¥3.08 (bull), the price of ¥21.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Tellgen Corp reported revenue of 364M CNY in FY2025 versus 655M CNY in FY2021, a compound −13.7%/yr. Reported net income was 3.6M CNY in FY2025, compounding −61.4%/yr from FY2021.
Key figures
Market cap 3.4B CNY (≈ $516M) · P/E ratio 265.1 · P/S ratio 2.61 · EPS (TTM) ¥0.0800 · Dividend yield 0.7% · Net margin 1.0% · Return on equity 0.7% · Return on assets (EBIT) 5.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 90% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −89%, 300642 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1500 to ¥8.66). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥1.72Fair Value ¥2.32Bull ¥3.08
Price ¥21.21 · Upside -89.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF¥4.72¥6.79¥9.5781
Growth DCF¥4.74¥6.53¥8.7879
Residual Income¥5.55¥5.06¥4.6976
All 25 models by family
DCF Models
FCF DCF¥4.72¥6.79¥9.5781
5Y Revenue Exit¥3.22¥4.52¥6.1173
5Y EBITDA Exit¥5.37¥8.57¥12.2975
5Y P/E Exit¥2.18¥2.57¥2.9372
10Y Revenue Exit¥3.73¥5.00¥6.6168
10Y EBITDA Exit¥5.05¥7.58¥10.9368
10Y P/E Exit¥3.18¥3.76¥4.3865
Earnings-Based
Graham-Dodd¥0.1500¥0.4800¥0.640064
Lynch FV¥0.1100¥0.1500¥0.200061
PEG = 1.0¥0.1100¥0.1500¥0.200057
EPV¥1.71¥1.92¥2.0974
Dividend Discount
Gordon GGM¥1.38¥2.49¥3.4268
DDM Multi-Stage¥1.38¥2.17¥2.6667
Multiples
P/E Multiple¥0.3600¥0.4900¥0.610063
P/S Multiple¥0.2800¥0.3800¥0.470058
P/B Multiple¥0.2800¥0.3800¥0.470055
EV/EBIT¥3.20¥4.21¥5.2266
EV/EBITDA¥6.54¥8.66¥10.7867
EV/Revenue¥2.33¥3.26¥4.1954
Asset-Based
NCAV (Graham)¥4.40¥5.89¥8.7954
Growth DCF
Growth DCF¥4.74¥6.53¥8.7879
Rev-Margin DCF¥3.22¥4.58¥6.1773
Economic Profit
Residual Income¥5.55¥5.06¥4.6976
ROIC Compounder¥1.71¥1.92¥2.0972
Growth Earnings
Growth-Adj P/E¥0.3000¥0.4300¥0.560067
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−52.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−53.0%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−53.0% vs −27.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +24.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−89.1% · Bottom 25%
Profitability
Return on equity (TTM)0.7% · Below median
Return on assets0.8% · Below median
Net margin (TTM)3.1% · Below median
Operating margin (TTM)22.3% · Top 25%
Growth and dividend
Revenue growth24.4% · Top 25%
Dividend yield (TTM)0.7% · Bottom 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (TTM)265.1× · Priciest 25%
P/B2.42× · Pricier than median
P/S (TTM)8.79× · Priciest 25%
P/FCF45.4× · Priciest 25%
EV/EBITDA49.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 9
FUTURE (revenue growth)100· sector 31
PAST (return on equity)3· sector 16
HEALTH (low debt)87· sector 98
DIVIDEND (yield)14· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tellgen Corp Fair Value". https://www.fairvalue-calculator.com/stock/300642
Frequently asked questions
Is Tellgen Corp (300642) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of ¥2.32 versus a price of ¥21.21, about −89% upside (overvalued).
What is the fair value of 300642?
Our model-based fair value for Tellgen Corp is ¥2.32 (as of Oct 4, 2026), built from audited fundamentals. The current price: ¥21.21.
What is the quality score of 300642?
Tellgen Corp has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tellgen Corp (300642)?
Our model-based price target is the fair value of ¥2.32 (as of Oct 4, 2026) from 25 valuation models. Cautious scenario ¥1.72, optimistic scenario ¥3.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Tellgen Corp stock forecast for 2026?
Our models put fair value at ¥2.32, about −89% upside versus a price of ¥21.21 (overvalued). Cautious scenario ¥1.72, optimistic scenario ¥3.08. The calculation is refreshed regularly with new filings.
What is the revenue of Tellgen Corp (300642)?
Tellgen Corp reported trailing-twelve-month revenue of about 392M CNY (latest available figure, as of Oct 4, 2026).
Does Tellgen Corp pay a dividend?
Tellgen Corp currently shows a dividend yield of about 0.71% relative to its recent price (as of Oct 4, 2026).
What growth is priced into Tellgen Corp (300642)?
For today's price to be fair in a discounted-cash-flow model, Tellgen Corp would have to grow free cash flow by +26.5 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.8 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of 300642 use?
Our models discount Tellgen Corp at 10.4 %: a base by market capitalisation (small), damped by beta 0.28, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tellgen Corp that is +26.5 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Tellgen Corp (300642) delivered so far?
Over the past 5 years revenue at Tellgen Corp grew -5.8 % a year. The price currently implies +26.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tellgen Corp (300642) growing?
The median revenue growth in the sector is +5.3 % a year. That is the yardstick for the growth priced into Tellgen Corp (+26.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tellgen Corp (300642)?
The free-cash-flow yield on the price is 2.20 %: that much free cash flow Tellgen Corp produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tellgen Corp (300642)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tellgen Corp it is ¥2.32 per share (as of Oct 4, 2026), against a price of ¥21.21. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Tellgen Corp stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 300642 trades above its calculated fair value: price ¥21.21, fair value ¥2.32, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300642?
No. The price is what the market pays today (¥21.21); the fair value is what the company's own numbers justify (¥2.32). For Tellgen Corp the two are ¥18.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tellgen Corp worth?
The market values Tellgen Corp at about 3.4B CNY (market capitalisation, as of Oct 4, 2026). Per share that is ¥21.21; our models calculate a fair value of ¥2.32 per share.
What do the bullish and bearish scenarios say about 300642?
Our models span a range for Tellgen Corp: cautious scenario ¥1.72, base ¥2.32, optimistic ¥3.08 per share (as of Oct 4, 2026, price ¥21.21). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300642?
Tellgen Corp trades at a price-to-earnings ratio of 265.1 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥2.32 is built from several models across several years. Other multiples: P/B 2.4, P/S 8.8, EV/EBITDA 49.7.
How solid is the balance sheet of Tellgen Corp (300642)?
Balance-sheet figures for Tellgen Corp (as of Oct 4, 2026): return on equity 0.7%, debt of 0.25 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 300642 from its 52-week high?
Tellgen Corp trades at ¥21.21, about 24% below its 52-week high of ¥27.92 and 90% above the low of ¥11.19 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.32 is for.
Which stocks are comparable to Tellgen Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tellgen Corp stock attractive at the current price?
The data as of Oct 4, 2026: price ¥21.21, calculated fair value ¥2.32 (−89%), Quality Score 57/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300642 calculated?
We run Tellgen Corp through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Tellgen Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tellgen Corp (300642)?
The closing price on Oct 9, 2026 was ¥21.21. Our model-based fair value is ¥2.32, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tellgen Corp right now?
The price sits above even our optimistic bull case (¥3.08). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Tellgen Corp (300642) come from?
Earnings per share at Tellgen Corp grew +4.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +14.9 %, EBIT margin −9.6 %, tax rate +1.0 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tellgen Corp
How large is the market capitalisation of Tellgen Corp (300642)?
The market capitalisation of Tellgen Corp is 3.4B CNY (≈ $516M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tellgen Corp (300642)?
The price-to-sales ratio of Tellgen Corp is 2.61 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tellgen Corp (300642)?
Earnings per share at Tellgen Corp are ¥0.0800 (price ÷ EPS = P/E 265.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tellgen Corp (300642)?
The dividend yield of Tellgen Corp is 0.7% (payout 188%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tellgen Corp (300642)?
The net margin of Tellgen Corp is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tellgen Corp (300642)?
The return on equity (ROE) of Tellgen Corp is 0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tellgen Corp (300642)?
On an EBIT basis the return on assets of Tellgen Corp is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tellgen Corp (300642)?
The operating margin of Tellgen Corp is 22.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tellgen Corp (300642)?
Revenue at Tellgen Corp is growing +24.4% versus a year earlier (3y avg −20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tellgen Corp (300642)?
Earnings per share at Tellgen Corp are growing +640% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Tellgen Corp (300642) hold?
Tellgen Corp holds more cash than debt, 212M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Tellgen Corp in the live analysis
One click puts Tellgen Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
